AzTrials
AzTrials

Age-Related Macular DegenerationPhase 1NCT03178149

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

A Phase 1 study testing ASP7317, tacrolimus and trimethoprim-sulfamethoxazole in people with Age-Related Macular Degeneration, run by Astellas Institute for Regenerative Medicine at 20 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of the eye. There are 2 types of AMD - wet AMD and dry AMD. Read more about this study

Who is it for?
Ages 50 years and older
Conditions the study is for
Age-Related Macular Degeneration
What is being tested?
ASP7317, tacrolimus and trimethoprim-sulfamethoxazole
Could I receive a placebo?
No, everyone receives an active treatment
How many people
42 participants
Where
20 sitesUnited States
Study dates
13 Jul 2018to 31 Dec 2027
Phase
Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • General Inclusion Criteria
  • Participant must be willing to take tacrolimus and willing to discontinue any medications that have a known strong interaction with tacrolimus.
  • Participant is able and willing to undertake all scheduled visits and assessments up to the week 52 visit.
  • Participant who is taking an antidepressant must be on a stable and effective dosage and must be willing to take it reliably for as long as it is required.
  • Participant must be willing and medically suitable to undergo monitored anesthesia care during the vitrectomy and subretinal injection.
  • Participant agrees to conform to local and institutional policies regarding active COVID-19 infections.
Show all 28Show fewer
  • Participant agrees not to participate in another interventional study until the 52-week visit has been completed.
  • Female participant is not pregnant or at least 1 of the following conditions apply:
  • Not a woman of childbearing potential (WOCBP)
  • WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 52 weeks after investigational product (IP) administration.
  • Female participant must agree not to breastfeed starting at screening and throughout the study period and for 52 weeks after IP administration.
  • Female participant must not donate ova starting at first dose of IP and throughout the study period and for 52 weeks after IP administration.
  • Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 52 weeks after IP administration.
  • Male participant must not donate sperm during the treatment period and for 52 weeks after IP administration.
  • Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 52 weeks after IP administration.
  • Ocular Inclusion Criteria: Study Eye (Both Groups 1 and 2)
  • Participant has bilateral AMD and geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) in the study eye. GA is defined as sharply demarcated areas of loss of the retinal pigment epithelial/epithelium (RPE). While having bilateral GA remains the preferred enrollment criterion, it is not a requirement and GA only in the study eye is admissible, as long as both eyes exhibit AMD.
  • Participant has no known history of choroidal neovascularization (CNV) (wet AMD) in either eye prior to enrollment in the trial and no evidence of prior or active CNV with optical coherence tomographyangiography (OCT-A) or indocyanine green angiography (ICG-A), as assessed by the reading center.
  • Participant has absence of exudation as assessed by fluorescein angiography (FA) and spectral domain-optical coherence tomography (SD-OCT).
  • Participant has sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging.
  • Participant is pseudophakic.
  • Ocular Inclusion Criteria: Study Eye (Group 1 only)
  • For cohort 1, the participant has a BCVA between light perception and </=23 Early Treatment Diabetic Retinopathy study (ETDRS) letters at the screening visit. For cohorts 2 and 3, the participant has a BCVA score between 15 (>/= 20/500) and 37 (</=20/200) ETDRS letters at the screening visit.
  • Participant has the total GA area </=30.5 mm^2 (</=12 disc areas [DA]).
  • Ocular Inclusion Criteria: Study Eye (Group 2 only)
  • Participant has BCVA score between 38 (>20/200) and 65 (</=20/50) ETDRS letters during the screening visit.
  • Participant has the total GA area of >/= 2.54 mm^2 and </= 20.4 mm^2 (>/=1 and </=8 DA, respectively) and must reside completely within the fundus autofluorescence (FAF) imaging field (Field 2 to 30 degree image centered on the fovea).
  • Participant has a difference in mean mesopic sensitivity </=2 dB between 2 tests at screening. If not </=2 dB, a third test may be conducted and mean values between the second and third assessments must be </=2 dB.

Who cannot join

  • General Exclusion Criteria
  • Participant has a history of recurrent varicella zoster virus (VZV) infection or a clinical diagnosis of VZV infection within 4 weeks of the baseline visit or positive anti-VZV immunoglobulin M (IgM). Being positive for immunoglobulin G (IgG), indicative of a past infection (or vaccination), is not an exclusionary criterion.
  • Participant has a history of recurrent cytomegalovirus (CMV) infection or a clinical diagnosis of CMV infection within 4 weeks of the baseline visit or positive anti-CMV IgM. Being positive for IgG, indicative of a past infection, is not an exclusionary criterion.
  • Participant has a positive tuberculosis (TB) test during the screening period by an interferon gamma release assay (e.g., QuantiFERON) within the 6 months prior to the screening. If a participant has tested negative for TB within the 6 months prior to the screening visit, retesting is not required unless clinically indicated.
  • Participant has a history or suspected active infection of toxoplasmosis or presence of elevated immunoglobulin M (IgM) toxoplasmosis titer within 4 weeks of the baseline visit.
  • Participant has an active infection (ocular or non-ocular) requiring the prolonged or chronic use of antimicrobial or anti-infective agents.
Show all 45Show fewer
  • Participant has a current malignancy or history of malignancy within the past 5 years, except non-metastatic basal or squamous cell carcinoma or keratoacanthoma or Bowen's disease or carcinoma-in-situ of the cervix that has been successfully treated.
  • Participant has a history of a solid organ or bone marrow transplant.
  • Participant has any condition that would prohibit the use of systemic immunosuppression with tacrolimus.
  • Participant is receiving or has received any immunosuppressive therapy (IMT) (other than topical, inhaled or low dose systemic corticosteroid use not exceeding 7.5 mg of prednisone daily [or equivalent]) within 6 weeks or 5 plasma half-lives, whichever is longer, prior to the administration of adjunct study medications.
  • Participant has a history of myocardial infarction in previous 12 months and whose disease is either unstable and/or symptomatic (e.g., angina, dyspnea, etc.).
  • Participant has electrocardiogram (ECG) results that are clinically significant and could either jeopardize the safety of the participant, impact the participant's ability to comply with study visit schedule or impact the validity of the study results. Participants with a mean Fridericia-corrected QT interval of > 430 ms (for males) and > 450 ms (for females) at screening must be cleared by a cardiologist prior to the baseline visit.
  • Participant has a study day diastolic blood pressure > 95 mmHg, at either the screening or baseline visit. Study day blood pressure is defined as the average of the second and third readings at a study visit. If the study day blood pressure exceeds the limits, 1 additional triplicate can be taken.
  • Participant has an estimated glomerular filtration rate (eGFR) of </= 30 mL/min, calculated by the chronic kidney disease epidemiology collaboration (CKD-EPI) equation.
  • Participant has an alanine aminotransferase (ALT), aspartate aminotransferase (AST) or gamma- glutamyltransferase (GGT) and total bilirubin (TBL) >/= 2 times the upper limit of normal (ULN).
  • Participant has severe anemia (hemoglobin < 9 g/dL [male] or hemoglobin < 8 g/dL [female]), leucopenia (white blood cell count < 2500/mm^3), thrombocytopenia (platelet count < 80000/mm^3) or polycythemia (hematocrit > 54% [male] or hematocrit > 49% [female]).
  • Participant has a hemoglobin A1c > 8.5%.
  • Participant has a clinically significant coagulopathy (i.e., activated partial thromboplastin time [aPTT] >/= 1.5 times the ULN and/or prothrombin time adjusted for the international normalized ratio [PT-INR] >/=2.0).
  • Participant has serology results indicative of having syphilis, Lyme disease, human immunodeficiency virus infection or active infection with hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), or varicella-zoster virus (VZV).
  • Participant has a history of familial adenomatous polyposis or inflammatory bowel disease (i.e., Crohn's disease, ulcerative colitis).
  • Participant has a history of allergic reaction to mydriatics or fluorescein.
  • Participant has a history of gene therapy or cell transplant therapy, including ASP7316, in a prior clinical study.
  • Participant has participated in any studies of an investigational drug or procedure (excluding vitamins and minerals for AMD studies) within 12 weeks prior to the screening visit, except as noted in below criterion.
  • Participant has participated with the study eye in any trial of a now FDA-approved complement inhibitor and/or has received an FDA approved complement inhibitor injection in the study eye within 24 weeks of the screening visit. After a washout period of 24 or more weeks, participants previously treated with a complement inhibitor will be eligible for participation, but participants will not be allowed to resume receiving any approved or investigational complement inhibitor in the study eye until the completion of the 52-week follow up period of the A7317-CL-0003 trial. Use of an FDA-approved complement inhibitor in the fellow, non-study eye is allowable.
  • Participant is unwilling to discontinue or avoid any CYP3A4 inducers (e.g., rifampin, rifabutin, phenytoin, carbamazepine, phenobarbital, St John's Wort) or participant is unwilling to discontinue or avoid protease inhibitors (e.g., nelfinavir, telaprevir, boceprevir), direct Factor Xa inhibitors, direct thrombin inhibitors, verapamil, diltiazem or erythromycin while taking tacrolimus.
  • Participant has a positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, opiates, cocaine, phencyclidine and methadone), unless the drug is taken for a documented medical condition and under the supervision of a physician.
  • Ocular Exclusion Criteria - Study Eye
  • Participant has macular degeneration due to causes other than AMD (e.g., Stargardt disease, cone rod dystrophy, toxic maculopathies, etc.)
  • Participant has developed CNV (wet AMD), also known as exudative AMD in either eye.
  • Participant has foveal sparing as determined by the presence of potentially viable photoreceptors, as evidenced by presence of an intact ellipsoid zone (EZ) </= 250 microns from the foveal center, based on reading center assessments at the screening visit.
  • Participant has a history of vitrectomy or submacular surgery, or any surgical intervention for AMD. Participants with a history of non-AMD-related surgical interventions (other than vitrectomy and submacular surgery) are potentially eligible if they meet all other inclusion/exclusion criteria.
  • Participant has prior treatment with photodynamic therapy (e.g., Visudyne®), intraocular external-beam radiation therapy or transpupillary thermotherapy.
  • Participant has a history of previous laser photocoagulation for choroidal neovascularization (CNV), diabetic macular edema, retinal vein occlusion and proliferative diabetic retinopathy.
  • Participant has an abnormality of vitreoretinal interface (e.g., tractional epiretinal membrane (ERM)), which can interfere with measurement of macular thickness or with the potential for macular structural damage.
  • Participant has a history of cystoid macular edema, retinal vascular occlusion, central serous chorioretinopathy, macular hole or retinoschisis in the study eye.
  • Participant has peripheral holes or other peripheral retinal lesions that are considered of rhegmatogenous potential (that is, with a risk of causing retinal detachment).
  • Participant has active or history of intraocular inflammation such as uveitis, chorioretinitis and optic neuropathy (other than glaucoma).
  • Participant has presence of an ocular toxoplasmosis scar.
  • Participant has nevus of Ota (oculodermal melanocytosis), a pigmented choroidal lesion showing characteristics associated with high risk of malignancy (e.g., elevated lesion) or a choroidal nevus in the macula.
  • Participant has pathologic myopia defined as a spherical equivalent of > 8.00 diopters or axial length > 28 mm at the screening visit, or myopic macular degeneration or posterior staphyloma.
  • Participant has glaucoma with uncontrolled intraocular pressure (IOP) (defined as IOP > 30 mmHg despite treatment with anti-glaucoma medication) or is using more than 2 agents to control IOP or a history of glaucoma-filtering surgery.
  • Participant has a history of corneal transplantation.
  • Participant has monocular vision; no light perception in the fellow eye or anophthalmic in the fellow eye.
  • Participant has a contraindication to pupil dilation.
  • Participant has any other ocular condition that can interfere with the assessment of imaging data.

Trial locations and contacts

20 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Astellas Institute for Regenerative Medicine contact

800-888-7704

astellas.registration@astellas.com

20 sites in 1 country

United States20 sites, 13 recruiting

  • University of Michigan Kellog Eye Center

    Ann Arbor, Michigan, 48105

    Recruiting

  • Emory University Eye Center

    Atlanta, Georgia, 30322

    Recruiting

  • Mass Eye and Ear Infirmary Ophthalmology Clinical Research Office

    Boston, Massachusetts, 02114

    Withdrawn

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts, 02114

    Recruiting

  • Retina Foundation of the Southwest

    Dallas, Texas, 75231

    Recruiting

  • Retina Consultants of Southwest Florida & National Ophthalmic Research Institute

    Fort Myers, Florida, 33912

    Withdrawn

  • Jules Stein Eye Institute

    Los Angeles, California, 90095

    Recruiting

  • Valley Retina Institute

    McAllen, Texas, 78503

    Completed

  • Tennessee Retina, PC

    Nashville, Tennessee, 37203

    Withdrawn

  • NJ Retina

    New Brunswick, New Jersey, 08901

    Withdrawn

  • University Retina and Macula Associates

    Oak Forest, Illinois, 60452

    Recruiting

  • Stanford University Byers Eye Institute

    Palo Alto, California, 94303

    Recruiting

  • Retina Specialty Institute

    Pensacola, Florida, 35203

    Recruiting

  • Mid-Atlantic Retina

    Philadelphia, Pennsylvania, 19107

    Recruiting

  • Retinal Consultants of Arizona LTD, Retinal Research Institute

    Phoenix, Arizona, 85053

    Withdrawn

  • Casey Eye Institute Oregon Health & Science University

    Portland, Oregon, 97239

    Recruiting

  • Kaiser Permanente Riverside Medical Center

    Riverside, California, 92505

    Recruiting

  • University of Washington

    Seattle, Washington, 98104

    Withdrawn

  • Deep Blue Retina

    Southaven, Mississippi, 38671

    Recruiting

  • Spokane Eye Clinical Research

    Spokane, Washington, 99204

    Recruiting

Other trials in United States

About this study

Official title: A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of the eye. There are 2 types of AMD - wet AMD and dry AMD. The advanced stage of dry AMD causes vision loss. This is known as geographic atrophy. AMD makes everyday tasks like reading or driving difficult.

ASP7317 is a potential new treatment for people with AMD. ASP7317 are human stem cells which have changed into cells found in the retina. ASP7317 is injected under the macula. It is hoped that ASP7317 will replace some of the damaged cells in the macula and improve vision for people with dry AMD.

Read more

Before ASP7317 is available as a treatment, the researchers need to check its safety and how well it is tolerated. They will also check for signs of improved vision. People taking part in this study will be older people who have geographic atrophy caused by dry AMD.

This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP7317. There will be 3 doses of ASP7317. These are low, medium and high numbers of cells. ASP7317 will be injected under the macula after the person is given either a local or a general anesthetic. To prevent the body from rejecting the cells, people will take tablets of tacrolimus a few days before receiving ASP7317 for up to a few weeks afterwards. Other medicines will be taken during this time to stop infections.

There will be 2 groups in the study. Group 1 will be people with severe vision loss and Group 2 will be people with moderate vision loss. There will be different small groups of people within Group 1 and Group 2, with each small group receiving 1 of the 3 doses of ASP7317.

Different small groups of people within Group 1 and Group 2 will receive lower to higher doses of ASP7317. Each small group will only receive 1 dose. Group 1 will start treatment first. At each dose, a medical expert panel will check the results of the first person in the group to decide if the rest of the group will receive the same dose. Then, the panel will decide if more people may receive the same dose or if the next group may receive the next highest dose. The panel will use the results from the lower dose of Group 1 to decide when Group 2 starts treatment (also at the lower dose). The panel will also use the results of the middle and higher doses in Group 1 to decide when and how many people in Group 2 can receive these doses. During the study, people will visit the clinic several times for up to 12 months (1 year).

During all visits, the study doctors will check for any medical problems after receiving ASP7317. Vital signs will be checked a few days before treatment with ASP7317 and up to about a month afterwards. Vital signs include blood pressure, pulse, and temperature. At some visits, the study doctors will also take blood samples for blood tests. At most visits, people will have eye tests and have different images, scans, and measurements taken. This could be for the affected eye or both eyes, depending on the test. People can visit the clinic extra times, if needed.

Read the detailed description

The study consists of the following periods: Screening (up to 60 days) and the Study Period (52 weeks post treatment).

Being tested
ASP7317, tacrolimus, trimethoprim-sulfamethoxazole, Acyclovir, Nystatin
Keywords
Geographic Atrophy, Age-related Macular Degeneration, ASP7317
Medical subject headings
Macular Degeneration, Geographic Atrophy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ASP7317Drug

    subretinal injection

  • tacrolimusDrug

    Also called FK506, Prograf®

    oral

  • trimethoprim-sulfamethoxazoleDrug

    Also called TMP/SMX

    oral

  • AcyclovirDrug

    oral

  • NystatinDrug

    oral

Study groups in NCT03178149
Study groupRoleWhat they receive
ASP7317 Dose Escalation/ Expansion (Group 1: Severe Vision Loss)ExperimentalSuccessive cohorts of participants (3 participants each) will be given escalating doses (cohort 1: low cells/dose; cohort 2: medium cells/dose; cohort 3: high cells/dose). Optional Expansion cohorts 3b will be opened after cohort 3 has been filled and 2b will be opened only if necessary. Dose levels for the expansion cohort will align with dose levels in escalation cohorts. Sentinel dosing will be required for each dose level. After the first participant in each dose cohort in Group 1 is dosed and followed for 4 weeks, the Independent Data Monitoring Committee (IDMC) will review the 4-week safety data and recommend if the second and third participants in Group 1 dose cohort may be treated. The IDMC recommendation to progress to the next dosing cohort will be based on 4-week follow-up safety review of the second and third participants in the preceding dose cohort. Participants will receive tacrolimus and other medicines to stop infection.
Receives: Drug: ASP7317; Drug: tacrolimus; Drug: trimethoprim-sulfamethoxazole; Drug: Acyclovir; Drug: Nystatin
ASP7317 Dose Escalation/ Expansion (Group 2: Moderate Vision Loss)ExperimentalSuccessive cohorts of participants (3 participants each) will be given escalating doses (cohort 4: low cells/dose; cohort 5: medium cells/dose; cohort 6: high cells/dose). Optional Expansion cohorts 5b and 6b will be opened after cohorts 5 and 6 have been filled. Dose levels for the expansion cohorts will align with dose levels in escalation cohorts. Cohort 4 (low cells/dose) dosing may begin after the IDMC recommendation to begin dosing in Group 1 cohort 2 (medium cells/dose). Cohort 5 (medium cells/dose) dosing may begin after IDMC review of the 4- week safety data of the first participant in Group 1 cohort 2 (medium cells/dose). Cohort 6 (high cells/dose) dosing may begin after IDMC review of 4-week safety data of the first participant in Group 1 cohort 3 (high cells/dose). Dosing in cohort 5 and 6 can only begin after the IDMC review and the completion of the preceding cohort. Participants will receive tacrolimus and other medicines to stop infection.
Receives: Drug: ASP7317; Drug: tacrolimus; Drug: trimethoprim-sulfamethoxazole; Drug: Acyclovir; Drug: Nystatin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety as assessed by incidence, frequency and severity of treatment emergent adverse events (TEAES)

    Adverse events (AEs) will be coded using Medical Dictionary for Regulatory Activities (MedDRA). An Adverse Event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of ASP7317, the adjunct study medications and the study procedures, whether or not considered related to ASP7317, the adjunct study medications and the study procedures.

    A Treatment Emergent Adverse Event (TEAE) is defined as an AE beginning or worsening in severity after starting administration of the adjunct study medication.

    Measured: Up to 52 Weeks

  2. Safety as assessed by incidence, frequency and severity of Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in congenital anomaly or birth defect or other medically important events.

    Measured: Up to 52 Weeks

  3. Safety assessed by Adverse Events (AEs) of special interest

    AEs of special interest include: ectopic or proliferative cell growth (retinal pigment epithelial/epithelium (RPE) or non-RPE) with adverse clinical consequence; any new diagnosis of an immune-mediated disorder; any new cancer, irrespective of prior history; unexpected, clinically significant AEs possibly related to the cell transplant procedure; immunosuppressive therapy (IMT) or ASP7317 (e.g., graft failure or rejection).

    Measured: Up to 52 Weeks

  4. Number of participants with cellular graft failure or rejection

    Evidence of cellular graft failure or rejection will be assessed by best corrected visual acuity (BCVA), slit lamp examination, dilated indirect ophthalmoscopy, fundus photographs, spectral domain-optical coherence tomography (SD-OCT) and fluorescein angiography (FA), when performed.

    Measured: Up to 52 Weeks

  5. Incidence of cellular graft failure or rejection

    Evidence of cellular graft failure or rejection will be assessed by best corrected visual acuity (BCVA), slit lamp examination, dilated indirect ophthalmoscopy, fundus photographs, spectral domain-optical coherence tomography (SD-OCT) and fluorescein angiography (FA), when performed.

    Measured: Up to 52 Weeks

Secondary outcomes (12)

  1. Mean change from baseline in area of Geographic Atrophy (GA) (mm^2) in study eye and fellow eye

    GA will be measured by blue-light fundus autofluorescence (FAF) (definitely decreased autofluorescence (DDAF)) and spectral domain-optical coherence tomography (SD-OCT) (area of ellipsoid zone (EZ) defect, area of outer nuclear layer (ONL) defect).

    Measured: Baseline, Weeks 26 and 52/End of Study (EOS)

  2. Mean percent change from baseline in area of Geographic Atrophy (GA) (mm^2) in study eye and fellow eye

    GA will be measured by blue-light fundus autofluorescence (FAF) (definitely decreased autofluorescence (DDAF)) and spectral domain-optical coherence tomography (SD-OCT) (area of ellipsoid zone (EZ) defect, area of outer nuclear layer (ONL) defect).

    Measured: Baseline, Weeks 26 and 52/End of Study (EOS)

  3. Mean change from baseline in the square root transformation of Geographic Atrophy (GA) area in study eye and fellow eye

    GA will be measured by blue-light fundus autofluorescence (FAF) (definitely decreased autofluorescence (DDAF)) and spectral domain-optical coherence tomography (SD-OCT) (area of ellipsoid zone (EZ) defect, area of outer nuclear layer (ONL) defect).

    Measured: Baseline, Weeks 26 and 52/End of Study (EOS)

  4. Mean change from baseline in best corrected visual acuity (BCVA) score in study eye and fellow eye

    BCVA will be measured by an assessor certified to use the Early Treatment of Diabetic Retinopathy Study (ETDRS) method. The BCVA score (in letter units) will be reported.

    Measured: Baseline, Weeks 1, 4, 6, 8, 12, 16, 26 and 52/End of Study (EOS)

  5. Mean change from baseline in mean sensitivity

    Mean sensitivity is the mean over all point-wise sensitivity zones. Point-wise sensitivity will be estimated using imaging measures obtained across all zones, treatment area and remote zone.

    Measured: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

  6. Mean change from baseline in point wise sensitivity (PWS) in treatment zone

    Point-wise sensitivity will be measured using sensitivity results obtained in the treatment zone as assessed by imaging criteria. Treatment zone in the study eye is defined as the area that corresponds to the subretinal bleb area identified by the day 0 fundus photograph.

    Measured: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

  7. Mean change from baseline in PWS in extended treatment zone

    Point-wise sensitivity will be measured using sensitivity results obtained in the extended treatment zone as assessed by imaging criteria. Treatment zone in the study eye is defined as the area that corresponds to the subretinal bleb area identified by the day 0 fundus photograph. Equivalent treatment zone in the fellow eye is defined as the quadrant that meets the criteria for the location for ASP7317 injection, as determined by the investigator.

    Measured: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

  8. Mean change from baseline in PWS in remote zone

    Point-wise sensitivity will be measured using sensitivity results obtained in the remote zone as assessed by imaging criteria. Remote zone is defined as retina outside and opposite to the treatment zone.

    Measured: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

  9. Mean change from baseline in PWS in extended remote zone

    Point-wise sensitivity will be measured using sensitivity results obtained in the extended remote zone as assessed by imaging criteria. Remote zone is defined as retina outside and opposite to the treatment zone.

    Measured: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

  10. Mean change from baseline in number of scotomatous points

    Scotomatous points (loci) will be measured using imaging measures. The number of scotomatous points is the total number of points that were not seen (<0 dB loci).

    Measured: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

  11. Mean change from baseline in fixation stability (95% bivariate contour ellipse area (BCEA))

    Fixation Stability will be measured using imaging measures obtained during the microperimetry testing session, categorized as stable, relatively unstable and unstable. Categorization of stability based on % of fixation points within a specified diameter circle centered in the gravitational center of all fixation points. Stable-More than 75% of fixation points located within 2 degree diameter circle. Relatively Unstable-Less than 75% of fixation points located within 2 degrees diameter circle, but more than 75% of fixation points located within 4 degree diameter circle. Unstable-Less than 75% of fixation points located within 4 degree diameter circle.

    Measured: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

  12. Mean change from baseline in distance of preferred retinal locus (PRL) from Fovea

    Distance of PRL from Fovea will be measured using imaging measures obtained during the microperimetry testing session. Participant with central vision loss obtain visual information with a preferred eccentric retinal area for visual tasks because of their central scotoma. This area is called the preferred retinal locus.

    Measured: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Jun 2017
  2. Study start13 Jul 2018
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
42 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03178149
Sponsor's protocol ID
7317-CL-0003
Status last verified
Aug 2026
First submitted
24 May 2017
Last updated
3 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No: Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing ASP7317, tacrolimus and trimethoprim-sulfamethoxazole in people with Age-Related Macular Degeneration, run by Astellas Institute for Regenerative Medicine at 20 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 28 inclusion and 45 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 20 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Astellas Institute for Regenerative Medicine (800-888-7704, astellas.registration@astellas.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety as assessed by incidence, frequency and severity of treatment emergent adverse events (TEAES) (time frame: Up to 52 Weeks). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03178149.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in